Journal
TRENDS IN MOLECULAR MEDICINE
Volume 17, Issue 7, Pages 347-362Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2011.01.015
Keywords
-
Funding
- Academy of Finland [130446, 130444, 140723]
- Finnish Cancer Organizations
- Sigrid Juselius Foundation
- Institute for Molecular Medicine Finland (FIMM)
- Academy of Finland (AKA) [130444, 130446, 140723, 130446, 140723, 130444] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF-VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the) members of the VEGF VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available